Ibrance Archives -

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set

Ibrance trial failure dashes Pfizer’s growth hopes for the drug

https://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/

Pfizer’s Ibrance has been approved for use by the NHS in England as a second-line treatment for advanced

NICE backs Ibrance for breast cancer via Cancer Drugs Fund

https://pharmaphorum.com/news/nice-backs-ibrance-for-breast-cancer-via-cancer-drugs-fund/

Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced

Scotland backs Pfizer’s Ibrance for breast cancer

https://pharmaphorum.com/news/scotland-backs-pfizers-ibrance-for-breast-cancer/

The FDA has expanded the use of Pfizer’s Ibrance to include use in breast cancer in men based

Real-world data unlocks Ibrance ok in male breast cancer

https://pharmaphorum.com/news/real-world-data-unlocks-ibrance-ok-in-male-breast-cancer/

In February 2015, Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed

Ibrance approval cemented as competition comes into view

https://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/

Ibrance